Compare BlackBerry Limited (BB) vs Eli Lilly And Co (LLY) Price & Performance

BlackBerry (BB) trades at $10.71, down 2.37% today, with a bullish technical signal from moving averages and RSI near oversold levels. Recent Q1 2026 earnings beat expectations with EPS of $0.06 versus $0.05 expected, driven by QNX software growth. Revenue for 2025 was $534.90M with a net loss of $79M, but 2026 projects a return to profitability. Positive news highlights QNX expansion into robotics and industrial automation.

Outlook is cautiously optimistic as the company's turnaround gains traction, but high valuation ratios (P/E 107.1) and mixed analyst sentiment (14% buy, 86% hold) suggest execution risks remain. Key opportunities include QNX's market penetration, while risks involve competitive pressures and achieving sustained profitability.

Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.

The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.